EyePoint Pharmaceuticals Shares Plunge Following Trial Failure

The clinical trial outcome revealed that DURAVYU did not achieve the prespecified primary goal of improving best-corrected visual acuity compared to the standard on-label aflibercept treatment. While the company reported secondary benefits, including a 42% reduction in treatment burden, these results were overshadowed by the primary failure and revelations regarding patient data. During an investor call, CEO Jay S. Duker addressed discrepancies in a 4% asymmetric patient cohort, attributing visual loss in several cases to geographic atrophy, glaucoma, or detached retinas. Investors had not been previously alerted to the risk that such asymmetric results could jeopardize the study's success.

By midday on August 17, the stock remained down roughly 68%. Levi & Korsinsky is now evaluating potential claims for shareholders who suffered losses, emphasizing that eligibility extends to those who purchased the stock regardless of whether they currently hold the shares. The firm has opened a review process for affected investors to determine the viability of recovering financial damages.